Open Access

Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy

  • Authors:
    • Liang Li
    • Shuchen Liu
    • Liyuan Liu
    • Zhongbing Ma
    • Man Feng
    • Chunmiao Ye
    • Wenzhong Zhou
    • Yongjiu Wang
    • Lu Liu
    • Fei Wang
    • Lixiang Yu
    • Fei Zhou
    • Yujuan Xiang
    • Shuya Huang
    • Qinye Fu
    • Qiang Zhang
    • Dezong Gao
    • Zhigang Yu
  • View Affiliations

  • Published online on: August 7, 2018     https://doi.org/10.3892/etm.2018.6584
  • Pages: 2949-2959
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The expression of insulin‑like growth factor‑1 receptor (IGF‑1R), which is involved in the genesis and progression of breast cancer, is thought to be associated with the overall survival (OS) of patients. However, the predictive and prognostic significance of the IGF‑1R expression in breast cancer remains controversial. The present study aimed to identify the factors associated with the levels of phosphorylated (p)‑IGF‑1R in breast cancer, their impact on the outcomes of breast cancer patients, and the prognostic value of alterations of p‑IGF‑1R during neoadjuvant chemotherapy (NAC). The present study included 348 female breast cancer patients whose paraffin‑embedded tumor tissue sections had been collected by biopsy and/or resection, among which the pre‑NAC and post‑NAC sections were available from 40 patients. Human epidermal growth factor receptor 2 (HER2) positivity and molecular subtype were significantly associated with the presence of p‑IGF‑1R in the tumor tissue (P<0.05). Patients with p‑IGF‑1R present in the tumor tissue had a shorter OS (P=0.003). The p‑IGF‑1R levels in the tumor after NAC differed significantly from those prior to NAC (P=0.005); however, this alteration in p‑IGF‑1R levels was not associated with a shorter OS. In parallel with HER2, p‑IGF‑1R appears to be a promising indicator for predicting clinical outcomes and may be an attractive target for improving the efficacy of antitumor therapy, particularly for patients with HER2‑negative, estrogen receptor‑positive and luminal B tumors.
View Figures
View References

Related Articles

Journal Cover

October 2018
Volume 16 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, L., Liu, S., Liu, L., Ma, Z., Feng, M., Ye, C. ... Yu, Z. (2018). Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy. Experimental and Therapeutic Medicine, 16, 2949-2959. https://doi.org/10.3892/etm.2018.6584
MLA
Li, L., Liu, S., Liu, L., Ma, Z., Feng, M., Ye, C., Zhou, W., Wang, Y., Liu, L., Wang, F., Yu, L., Zhou, F., Xiang, Y., Huang, S., Fu, Q., Zhang, Q., Gao, D., Yu, Z."Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy". Experimental and Therapeutic Medicine 16.4 (2018): 2949-2959.
Chicago
Li, L., Liu, S., Liu, L., Ma, Z., Feng, M., Ye, C., Zhou, W., Wang, Y., Liu, L., Wang, F., Yu, L., Zhou, F., Xiang, Y., Huang, S., Fu, Q., Zhang, Q., Gao, D., Yu, Z."Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy". Experimental and Therapeutic Medicine 16, no. 4 (2018): 2949-2959. https://doi.org/10.3892/etm.2018.6584